Silicon Valley R&D & Flex Investment Sales
Silicon Valley R&D Broker — The Corridor Where Tech, Biotech, and Capital Converge
Two decades of producer-level R&D and flex experience across Sunnyvale, Mountain View, Fremont, and Palo Alto research corridors. Lab, flex, and tech-occupant institutional disposition advisory.
R&D is the most resilient Bay Area asset class through every cycle
While office headlines dominated the post-2020 narrative, the Silicon Valley R&D corridor has quietly outperformed every other Bay Area asset class. Reason: tenant demand from biotech, semiconductor design, AI hardware, and tech-occupant manufacturing has structurally expanded while supply remains tightly constrained by zoning. Submarkets like Sunnyvale's Moffett Park, Mountain View's North Bayshore, and Fremont's Warm Springs continue to see pre-leasing on speculative product.
The institutional buyer pool for R&D is deeper and more focused than for general office: dedicated life science REITs, specialized R&D and lab sponsors, and a long tail of family-office capital see R&D as the "office-adjacent" asset class with secular tailwinds.
What makes R&D disposition different from office disposition: tenant build-out value, the difference between wet-lab-ready and dry-lab product, parking ratios, ceiling heights, dock-high access, and proximity to anchor research institutions all influence pricing more than location alone.
Career R&D experience
Career experience as a producer at a major national capital markets platform between 2004 and 2026 included substantial involvement in Silicon Valley R&D and flex production — institutional campus dispositions, off-market portfolio assemblage, single-tenant lab dispositions, and tech-occupant flex transactions across the Sunnyvale, Mountain View, Fremont, Palo Alto, San Jose, Milpitas, and South San Francisco research corridors.
See the career experience summary →
Transaction-level detail is available to qualified institutional principals under mutual NDA during the engagement-evaluation process.
How we underwrite and market R&D dispositions
R&D disposition is technical work. The institutional buyer pool will not engage on partial information. Our process is built to deliver complete information from day one.
Technical asset profile. Detailed build-out inventory: clean room class, vibration tolerances, power capacity, redundancy, HVAC, fume hood counts, biosafety levels, dock access, ceiling heights. This information determines which buyer pool is the right target.
Specialized buyer targeting. Beyond dedicated life science REITs, we maintain a network of specialized sponsors and tenant capital that transact selectively on R&D when the alignment is right. Many of these buyers don't bid through standard brokerage marketing — they need to be sourced directly.
Tenant intelligence layer. Where the asset has tenant rights of first offer, right of first refusal, or expansion options, the disposition strategy starts with the in-place tenant. Often the best buyer is already in the building.
Active R&D / flex submarket coverage
Related
R&D disposition strategy session
The R&D buyer universe is small and relationship-driven. The first conversation maps your asset against the active capital pools and identifies the right execution path — direct strategic, broad institutional, or tenant-driven.